期刊文献+

二肽基肽酶Ⅳ抑制剂的研究进展

下载PDF
导出
摘要 糖尿病(Diabetes Mellitus,DM)是一种常见的慢性代谢性疾病,近年来,全球糖尿病患者的数量急剧增加,预计到2030年将达到5.52亿[1]。目前,治疗2型糖尿病的口服药物主要有胰岛素分泌促进剂(磺酰脲类、瑞格列奈)、胰岛素增敏剂(双胍类、噻唑烷二酮类)和α-葡萄糖苷酶抑制剂(阿卡波糖),但它们长期服用会产生不同程度的副作用[2,3]。
出处 《湖北科技学院学报(医学版)》 2014年第5期450-453,共4页 Journal of Hubei University of Science and Technology(Medical Sciences)
基金 湖北科技学院糖尿病专项(ZX1302) 国家级大学生创新创业训练计划项目(201210927022)
  • 相关文献

参考文献21

  • 1IDF Diabetes Atlas:Global estimates of the prevalence of diabetes for 2011 and 2030[J].Diabetes Research and Clinical Practice,2011,94(3):311. 被引量:1
  • 2Gupta R,Walunj SS,Tokala RK,et al.Emerging drug candidates of dipeptidyl peptidase IV(DPP IV)inhibitor class for the treatment of type 2 diabetes[J].Current Drug Targets,2009,10(1):71. 被引量:1
  • 3仉媛媛,丛丽.格列奈类药物在肥胖2型糖尿病治疗中的系统评价[J].药品评价,2013(9):33-35. 被引量:6
  • 4Mentlein R,Gallwitz B,Schmidt WE.Dipeptidyl-peptidaseⅣhydrolyses gastric inhibitory polypeptide,glucagon-like peptide-1(7-36)amide,peptide histidine methionine and is responsible for their degradation in human serum[J].European Journal of Biochemistry,1993,214(3):829. 被引量:1
  • 5Havale SH,Pal M.Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes[J].Bioorganic&Medicinal Chemistry,2009,17(5):1783. 被引量:1
  • 6Elrick H,Stimmler L,Hlad CJ,et al.Plasma insulin response to oral and intravenous glucose administration[J].J Clin Endocrinol Metab,1964;24:1076. 被引量:1
  • 7Pei Z,Li X,Geldern TW,et al.Discovery and structureactivity relationships of piperidinone-and piperidine-constrained phenethylamines as novel,potent,and selective dipeptidyl peptidase IV inhibitors[J].Journal of Medicinal Chemistry,2007,50(8):1983. 被引量:1
  • 8Baetta R,Corsini A.Pharmacology of dipeptidyl peptidase-4 inhibitors[J].Drugs,2011,71(11):1441. 被引量:1
  • 9Cahn A,Raz I.Emerging gliptins for type 2 diabetes[J].Expert Opinion on Emerging Drugs,2013,18(2):245. 被引量:1
  • 10Noh YH,Lim HS,Jin SJ,et al.Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin,a dipeptidyl peptidase-IV inhibitor:A crossover drug-drug interaction study in healthy male Korean volunteers[J].Clinical Therapeutics,2012,34(5):1182. 被引量:1

二级参考文献16

  • 1Bickle JF. Meglitinide analogues: a review of clinical data focused on recent trials[J]. Diabetes Metab, 2006, 32(2): 113-120. 被引量:1
  • 2Sunaga Y, Gonni T, Shibasaki T, et al. The effect of mitiglinide KAD- 1229, a new anti-diabetic drug,on ATP-sensitive K+channels and insulin secretion:compa-rison with the sulfonylureas and nateglinide[J]. European Journal of Phar-macology, 2001, 314: 119-125. 被引量:1
  • 3Hollander PA, Schwarz SL, Gatlin MR, et al. Importance of early insulin secretion :comparison ofnateglinide and glyburide in previously diet-treated patients with type 2 diabetes[J]. Diabetes Care, 2001, 24(6): 983-988. 被引量:1
  • 4Kishikawa H, Okada Y, Kanda K, et al. Indication for type 2 diabetes mellitus [J]. JUOEG, 2005, 27(2): 179-188. 被引量:1
  • 5Taki H, Maki T, lso T, et al. Postmarketing study of nateglinide in Japan:treatment of medication-naive patients with type 2 diabetes[J]. Adv Ther, 2005, 22(6): 621-635. 被引量:1
  • 6Tentolouris N, Boutati E, Karambakalis N, et al. Acute nateglinide administration in subjects with type 2 diabetes:effects on postprandial metabolism, coagulation, and fibrinolysis[J]. Nutr Metab Cardivasc Dis, 2005, 15(1): 6-12. 被引量:1
  • 7Rizzo MR, Barbieri M, Grella R, et at. Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal- test study[J]. Diabetes Metab, 2005, 31(3 Pt1): 255-260. 被引量:1
  • 8Campbell IW. Nateglinide-current and future role in the treatment of patients with type 2 diabetes meHitus[J]. J Clin Pract, 2005, 59(10): 1218-1228. 被引量:1
  • 9Cerich J, Raskin P, Louis L, et al. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin[J]. Diabetes Care, 2005, 28(9): 2093-2099. 被引量:1
  • 10Ambavane V, Patil R, Ainapure SS. Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia[J]. J Postgrad Med, 2002, 48(3): 246-248. 被引量:1

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部